In this article included in The Globalisation of the Pharmaceutical Industry, the authors draw on their experience to develop lessons on how to establish a sustainable life sciences eco-system in middle-income countries (MICs) and low-income countries (LICs). They highlight the importance of different types of government policy (industrial policy, the regulatory framework, intellectual property, and improving access to medicines) and how success requires different stakeholders (public and private, international and national) to work together.
To read the article, click here.
The economic cost of living with a rare disease across Europe
Although rare diseases affect a relatively small number of patients, collectively there are an estimated 30 million people in Europe living with 6,000-7,000...